Granted Patent B2

US 12,624,110 · App. 18/480,071 · Granted May 12, 2026

Inventors: Jinhyung Ahn (Seongnam-si, KR); Sungwon An (Seongnam-si, KR); Dongin Kim (Seongnam-si, KR); Eunsil Sung (Seongnam-si, KR); Jaehyun Eom (Seongnam-si, KR); Sang Hoon Lee (Seongnam-si, KR); Weonkyoo You (Seongnam-si, KR); Juhee Kim (Seongnam-si, KR); Kyungjin Park (Seongnam-si, KR); Hyejin Chung (Seongnam-si, KR); Jinwon Jung (Seongnam-si, KR); Bora Lee (Seongnam-si, KR); Byungje Sung (Seongnam-si, KR); Yeunju Kim (Seongnam-si, KR); Yong-Gyu Son (Seongnam-si, KR); Seawon Ahn (Seongnam-si, KR); Daehae Song (Seongnam-si, KR); Jiseon Yoo (Seongnam-si, KR); Youngdon Pak (Seongnam-si, KR); Donghoon Yeom (Seongnam-si, KR); Yoseob Lee (Seongnam-si, KR); Jaeho Jung (Seongnam-si, KR)

Assignee: ABL Bio Inc.

C07K16/2863A61K47/6845C07K16/18C07K2317/31C07K2317/565C07K2317/567

Abstract

Claims (22)

1 . An anti-insulin-like growth factor 1 receptor (IGF1R) antibody or antigen binding fragment thereof, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein

(1) the VH comprises an H-CDR1 comprising SEQ ID NO: 1, an H-CDR2 comprising SEQ ID NO: 12, and an H-CDR3 comprising SEQ ID NO: 52,

and the VL comprises an L-CDR1 comprising SEQ ID NO: 98, an L-CDR2 comprising SEQ ID NO: 116, and an L-CDR3 comprising SEQ ID NO: 151;

or

(2) the VH comprises an H-CDR1 comprising SEQ ID NO: 1, an H-CDR2 comprising SEQ ID NO: 13, and an H-CDR3 comprising SEQ ID NO: 52,

and the VL comprises an L-CDR1 comprising SEQ ID NO: 98, an L-CDR2 comprising SEQ ID NO: 117, and an L-CDR3 comprising SEQ ID NO: 152.

2 . The anti-IGF1R antibody or antigen binding fragment thereof according to claim 1 , wherein the VH comprises one or more of

a heavy chain framework1 (H-FR1) comprising an amino acid sequence selected from SEQ ID NOs: 81-84,

an H-FR2 comprising SEQ ID NO: 85 or 86,

an H-FR3 comprising an amino acid sequence selected from SEQ ID NOs: 87-91, or

an H-FR4 comprising an amino acid sequence selected from SEQ ID NOs: 92-95.

3 . The anti-IGF1R antibody or antigen binding fragment thereof according to claim 1 , wherein the VL comprises one or more of

a light chain framework1 (L-FR1) comprising an amino acid sequence selected from SEQ ID NOs: 162-164,

an L-FR2 comprising SEQ ID NO: 165,

an L-FR3 comprising an amino acid sequence selected from SEQ ID NOs: 166-168, or

an L-FR4 comprising an amino acid sequence selected from SEQ ID NOs: 169-171.

4 . The anti-IGF1R antibody or antigen binding fragment thereof according to claim 1 , wherein the VH and the VL compromise:

(1) SEQ ID Nos: 219 and 338, respectively; or

(2) SEQ ID Nos: 222 and 341, respectively.

5 . The anti-IGF1R antibody or antigen binding fragment thereof according to claim 1 , wherein the antigen binding fragment of the anti-IGF1R antibody is selected from the group consisting of scFv, (scFv) 2 , scFv-Fc, Fab, Fab′ and F(ab′) 2 .

6 . A method of making a therapeutic molecule capable of crossing the blood-brain barrier of a subject, comprising linking the therapeutic molecule to the anti-IGF1R antibody or antigen-binding fragment of claim 1 .

7 . A method of delivering a therapeutic molecule across the blood-brain barrier of a subject in need thereof, comprising administering the therapeutic molecule to the subject, wherein the therapeutic molecule is linked to the anti-IGF1R antibody or antigen-binding fragment of claim 1 .

Priority Claims (1)

Continuity (5)

References Cited (161)